|Bid||296.32 x 1000|
|Ask||297.01 x 900|
|Day's Range||296.37 - 303.60|
|52 Week Range||151.47 - 387.40|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||60.08|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abiomed announces record revenue of $241 million , up 17% year over year, with 26.0% operating margin.
NEW YORK, NY / ACCESSWIRE / April 29, 2021 / ABIOMED, Inc. (NASDAQ:ABMD) will be discussing their earnings results in their 2021 Fourth Quarter Earnings call to be held on April 29, 2021 at 8:00 AM Eastern Time.
The final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization (PCI). The study evaluated the outcomes of 406 consecutive patients who presented with acute myocardial infarction cardiogenic shock (AMICS) at 80 participating sites throughout the United States. The study shows a protocol-based approach to increasing survival rates in cardiogenic shock is reproducible in both academic and community hospital settings. Results were presented today by Babar Basir, DO, director of the acute mechanical circulatory support program at Henry Ford Hospital and co-principal investigator of the study, at the 2021 Society of Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions.